MY182591A - Compositions for use in treating eye disorders using dipyridamole - Google Patents

Compositions for use in treating eye disorders using dipyridamole

Info

Publication number
MY182591A
MY182591A MYPI2015002196A MYPI2015002196A MY182591A MY 182591 A MY182591 A MY 182591A MY PI2015002196 A MYPI2015002196 A MY PI2015002196A MY PI2015002196 A MYPI2015002196 A MY PI2015002196A MY 182591 A MY182591 A MY 182591A
Authority
MY
Malaysia
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
topically
Prior art date
Application number
MYPI2015002196A
Other languages
English (en)
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
O D Ocular Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc, O D Ocular Discovery Ltd filed Critical Remedeye Inc
Publication of MY182591A publication Critical patent/MY182591A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2015002196A 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole MY182591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (fr) 2013-03-12 2014-03-11 Compositions destinées à être utilisées en traitement de troubles oculaires à l'aide de dipyridamole

Publications (1)

Publication Number Publication Date
MY182591A true MY182591A (en) 2021-01-26

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015002196A MY182591A (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Country Status (14)

Country Link
EP (1) EP2968328A4 (fr)
JP (1) JP6820658B2 (fr)
KR (2) KR20210010638A (fr)
CN (1) CN105188702B (fr)
AU (1) AU2014229371B2 (fr)
BR (1) BR112015022084A2 (fr)
CA (1) CA2905594A1 (fr)
CL (1) CL2015002627A1 (fr)
EA (1) EA035966B1 (fr)
IL (1) IL225179A (fr)
MX (1) MX2015012716A (fr)
MY (1) MY182591A (fr)
SG (2) SG11201507092QA (fr)
WO (1) WO2014141079A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180015090A1 (en) * 2015-01-28 2018-01-18 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001806A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables avec des impuretés réduites
WO2021001805A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables et leurs procédés de préparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
RU2008122978A (ru) * 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
WO2010056710A1 (fr) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions et procédés pour traiter des maladies ophtalmiques
EP2363126A1 (fr) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprenant une L-carnitine en tant que principe actif en combinaison avec le glucoside de l'hydroxykynurénine, pour la prévention et/ou le traitement de pathologies de l'oeil dues au rayonnement ultraviolet

Also Published As

Publication number Publication date
CL2015002627A1 (es) 2016-03-11
KR20150126021A (ko) 2015-11-10
IL225179A0 (en) 2013-06-27
MX2015012716A (es) 2016-07-06
CA2905594A1 (fr) 2014-09-18
KR20210010638A (ko) 2021-01-27
SG11201507092QA (en) 2015-10-29
IL225179A (en) 2017-01-31
EA035966B1 (ru) 2020-09-07
WO2014141079A1 (fr) 2014-09-18
EP2968328A4 (fr) 2016-11-23
EP2968328A1 (fr) 2016-01-20
AU2014229371B2 (en) 2018-05-10
BR112015022084A2 (pt) 2017-07-18
JP2016514123A (ja) 2016-05-19
SG10201706937UA (en) 2017-09-28
AU2014229371A1 (en) 2015-10-29
JP6820658B2 (ja) 2021-01-27
EA201591653A1 (ru) 2017-05-31
CN105188702B (zh) 2019-03-26
CN105188702A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX364486B (es) Derivados de piridazinona-amidas.
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EA201892726A1 (ru) Дейтерированный палбоциклиб
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UA115357C2 (uk) Похідні піридин-4-ілу
MX2016016404A (es) Metodos para el tratamiento del prurito.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
EP2910247A4 (fr) Compositions pour prévenir ou traiter des troubles cutanés allergiques, contenant les agents gpcr19 comme ingrédients actifs
EA201491878A1 (ru) Замещенные ксантиновые производные
MX366805B (es) Uso de sulfato de zinc coceth como un agente antibacteriano en contra de propionibacterium acnes.
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
NZ764041A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
IN2013MU01157A (fr)